Updated from April 14
The judge said the three challengers failed to prove the patent was invalid or unenforceable.
The stock was up $1.63, or 2.8%, to $58.75 in premarket trading."We have always been very confident that our patents are valid and enforceable and today's court ruling sends a clear message on the strength of those patents," said Sidney Taurel, Lilly's chairman, president and chief executive. Most analysts predicted Lilly would win the case, protecting the U.S. patent on an antipsychotic drug that produced $4.4 billion in worldwide sales last year, including $2.4 billion in the U.S. Zyprexa accounted for 32% of the company's total sales last year, and analysts say it contributes to an even greater percentage of operating profit. A Lilly loss would have crushed the stock and hurt annual earnings for the rest of the decade, analysts have said during the long patent battle. Some also have viewed the case as a litmus test for the enforceability of other pharmaceutical patents. On Thursday, nervous investors traded more than 15.8 million shares, or about five times the average daily trade for the past three months. The key Zyprexa patent was challenged by three companies -- Ivax (IVX), Teva Pharmaceutical Industries (TEVA - Get Report) and Dr. Reddy's Laboratories (RDY - Get Report). They argued that the patent, which Lilly says remains in force until 2011, was invalid. In premarket trading, shares of Ivax lost 73 cents, or 4%, to $17.75; shares of Teva were up 2 cents at $32.15; while shares of Dr. Reddy closed at $17.05 Thursday. Lilly had been fighting these patent challenges since 2001. Subsequently, the lawsuits were consolidated before a federal judge in Indianapolis, Lilly's home town. As an indication of the case's complexity, the actual trial was held in January and February of last year.